Genetically determined ABO blood group, secretor status, Lewis antigens, and panNEN risk
Samuel O Antwi, Erin E Carlson, Kari G Rabe, Teja Koganti, William R Bamlet, MAYO-RGC Project Generation, Regeneron Genetics Center, Thorvardur R Halfdanarson, Robert R McWilliams, Kirk J Wangensteen, Ann L Oberg · 2026
Read Genetically determined ABO blood group, secretor status, Lewis antigens, and panNEN risk by Samuel O Antwi, Erin E Carlson, Kari G Rabe, Teja Koganti, William R Bamlet, MAYO-RGC Project Generation, Regeneron Genetics Center, Thorvardur R Halfdanarson, Robert R McWilliams, Kirk J Wangensteen, Ann L Oberg (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13615866.txt.
Description
Antwi, Oberg and their co-authors test whether blood group and related gene markers affect risk of a rare pancreatic tumor. Their work, listed for 2026, contrasts this tumor with the more common pancreatic cancer, where non-O blood group is a known risk marker.
The case-control study used more than a thousand confirmed cases and a far larger control group from the same clinic system. Blood group, secretor status and Lewis traits were inferred from gene data. None linked to tumor risk, alone or in combination. Given the study's power, the authors say these pathways are unlikely to be major drivers here.
Catalog record
| CREATOR | Samuel O Antwi, Erin E Carlson, Kari G Rabe, Teja Koganti, William R Bamlet, MAYO-RGC Project Generation, Regeneron Genetics Center, Thorvardur R Halfdanarson, Robert R McWilliams, Kirk J Wangensteen, Ann L Oberg |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |